Approved In China
Mazdutide
Also known as IBI362 · LY3305677
At a glance
- What it is
- Glucagon/GLP-1 dual agonist approved in China, not by FDA.
- Evidence
- Clinical trialsHow the tiers workGLORY-2 (JAMA, 7 June 2026, NCT06164873, n=461 across 27 Chinese hospitals) reported −16.65% against −1.50% on placebo at 60 weeks on 9 mg weekly, with 84.3% against 33.1% reaching at least 5% loss. Why this tier
- Half-life
- About 6 to 17 days in early trials, varying widely from person to person
- From Phase 1b trials, PubMed 34430840 and 35750681
- Routes
- Subcutaneous
- Category
- Metabolic
- WADA
- We do not state a status
Putting Mazdutide on a schedule, with the vial it comes from and a log of each dose, happens in the app: Claritide for iPhone.
Why this tier
GLORY-2 (JAMA, 7 June 2026, NCT06164873, n=461 across 27 Chinese hospitals) reported −16.65% against −1.50% on placebo at 60 weeks on 9 mg weekly, with 84.3% against 33.1% reaching at least 5% loss. In the earlier GLORY-1 trial, the 4 mg and 6 mg arms gave −11.00% and −14.01% at 48 weeks against +0.30% on placebo on the treatment-policy estimand (NEJM); Innovent’s headline figures, −12.05% and −14.84%, are the efficacy estimand. The caveat is the population: Chinese adults, with a lower baseline BMI and a younger mean age (33.9 years) than Western obesity trials, so the generalisability of the effect size to a different population is genuinely uncertain.
What it is
Mazdutide is a glucagon and GLP-1 dual agonist that originated at Eli Lilly and is licensed to Innovent. China approved it for chronic weight management in June 2025 and later for glycaemic control in type 2 diabetes. It is not FDA-approved. Its pivotal data comes from Chinese adults, a population with a lower baseline BMI and a younger mean age than Western trials, which is the caveat that makes the record worth carrying.
How it works
The same dual mechanism as survodutide: GLP-1 receptor agonism for appetite suppression, slowed gastric emptying and glucose-dependent insulin release, plus glucagon receptor agonism for increased energy expenditure and hepatic fat oxidation, with the GLP-1 arm offsetting glucagon’s effect on blood sugar.
Commonly researched ranges
- GLORY-1 Phase 3 doses · the two approved strengths4–6 mg
Both arms of GLORY-1, and both approved by China’s NMPA for chronic weight management on 27 June 2025. Stated first because the record previously showed only the 9 mg dose, which is the one that is not approved anywhere.
- GLORY-2 Phase 3 dose9 mg
The dose in GLORY-2 (NCT06164873). Its supplementary application was accepted for NMPA review in November 2025, and we found no approval as of 27 September 2026; nothing about mazdutide is approved in the US or the EU.
| Phase | Amount | Frequency | Timing | Note |
|---|---|---|---|---|
| GLORY-1 Phase 3 doses · the two approved strengths | 4–6 mg | Once weekly for 48 weeks | Not established in available literature | Both arms of GLORY-1, and both approved by China’s NMPA for chronic weight management on 27 June 2025. Stated first because the record previously showed only the 9 mg dose, which is the one that is not approved anywhere. |
| GLORY-2 Phase 3 dose | 9 mg | Once weekly for 60 weeks | Not established in available literature | The dose in GLORY-2 (NCT06164873). Its supplementary application was accepted for NMPA review in November 2025, and we found no approval as of 27 September 2026; nothing about mazdutide is approved in the US or the EU. |
- Cycle guidance
- Not established in available literature
- Goals
- Fat loss
Where this sits with the FDA
Approved by China’s NMPA and not by FDA. An approval in one jurisdiction is a real regulatory event and it does not make a product lawful, labelled or supply-chain-verified in another.
Last change · 1 June 2025 · China’s National Medical Products Administration approved mazdutide for chronic weight management in June 2025; our source does not give an exact day.
Primary sourceWADA status
Not named on the 2026 Prohibited List. We could not determine a classification and do not state one.
We looked and could not resolve it. This is not the same as "not prohibited". Treat it as unresolved and check with your federation before competing.
Mixing recipes our sources document
Not established in available literature. Use the calculator with the figures printed on your own vial.
Open the calculator
Week by week
Not established in available literature.
Side effects
Common
- Vomiting53.1% in trials
- Nausea46.9% in trials
- Diarrhoea39.4% in trials
Uncommon
- Discontinuation for adverse events2.9% in trials
Contraindications and interactions
Do not use if
Not established in available literature.
Interactions
Not established in available literature.
Absence from this list does NOT mean safety. It means lack of research.
Storage and cost
- Storage
- Our sources publish no reconstitution or storage protocol for mazdutide.
- Cost
- Not established in available literature
Mazdutide in full
Limited coverage
Mazdutide is a glucagon and GLP-1 dual agonist, originated at Eli Lilly and licensed to Innovent. Once weekly, subcutaneous. Approved by China's National Medical Products Administration for chronic weight management in June 2025, and later for glycaemic control in type 2 diabetes. Not FDA-approved.
The data
GLORY-2, published in JAMA on 7 June 2026: NCT06164873, 461 participants across 27 Chinese hospitals, 9 mg weekly for 60 weeks. Weight change −16.65% against −1.50% on placebo, with 84.3% against 33.1% reaching at least 5% loss. Discontinuation for adverse events was 2.9% against 0%.
Gastrointestinal effects were substantial: vomiting 53.1%, nausea 46.9%, diarrhoea 39.4%.
In the earlier GLORY-1 trial, the 4 mg and 6 mg arms gave −11.00% and −14.01% at 48 weeks against +0.30% on placebo, on the treatment-policy estimand published in NEJM. Innovent’s headline figures for the same arms, −12.05% and −14.84%, are the efficacy estimand: the same trial, a different question.
The caveat that is the point
The pivotal data comes from Chinese adults, a population with a lower baseline BMI and a younger mean age than Western obesity trials, at 33.9 years.
That is not a criticism of the trial. It is a statement about what the number transfers to. Percentage weight loss is not obviously portable across populations with different starting body composition, different baseline metabolic disease burden and different average age. A 16.65% result in a 34-year-old cohort with a lower starting BMI is a different fact from a 16.65% result in a 50-year-old Western cohort, and it is the kind of distinction that disappears entirely when a number is copied into a comparison table.
Mazdutide is being sold into the US on the strength of that number.
Sources
- 1JAMA, 7 June 2026 · GLORY-2, mazdutide 9 mg weekly for 60 weeks, n=461
- 2ClinicalTrials.gov NCT06164873 · GLORY-2 (CIBI362B302), Innovent (record last updated August 2024; read 27 September 2026)
- 3Innovent · mazdutide receives NMPA approval for chronic weight management
- 4Innovent, 25 May 2025 · GLORY-1 published in NEJM: the 4 mg and 6 mg arms, with both estimands (dose review, 2026-08-17; read 27 September 2026)
- 5Ji et al., NEJM, 25 May 2025 · GLORY-1, mazdutide 4 mg and 6 mg for 48 weeks, n=610, treatment-policy estimand
- 6Innovent, 25 November 2025 · the mazdutide 9 mg supplementary application accepted for NMPA review, i.e. not approved; no approval found as of 27 September 2026
Every record in this library is free to read, and it stays free. Your own schedule, vials and log live in the app: Claritide for iPhone.